Amylyx Pharmaceuticals Announces Collaboration with Gubra A/S for Development of Long-Acting GLP-1 Receptor Antagonist
On December 30, 2024, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) revealed a strategic collaboration with Gubra A/S for the development of a potential novel long-acting GLP-1 receptor antagonist. The agreement entails identifying a lead development candidate following a screening period for entry into Investigational New Drug (“IND”)-enabling studies. Once the long-acting GLP-1 receptor antagonist is identified, […]
More Stories
Why the US Denied a Request From Mexico for Water
By Autumn Spredemann Mexico’s delinquent water deliveries, in violation of an 81-year-old treaty with the United States, have exposed years...
4 Indicted as US Officials Disrupt Marriage Fraud Operation: ICE
By Jack Phillips U.S. immigration officials announced on Monday that they had disrupted a marriage fraud operation in Maryland, and...
How Junk Food Leads to Junk Sleep
By Zena le Roux “If something is made in a factory, it’s probably better left there—not in your body,” said...
Coca-Cola’s Earnings Beats Estimates, Sees Market Challenges ‘Manageable’
By Panos Mourdoukoutas Coca-Cola reported better-than-expected earnings for the first quarter despite lower sales due to market challenges. However, it...
US Job Openings Slide to 6-Month Low, Layoffs Fall
By Andrew Moran Job vacancies declined sharply in March, but little change in new hires and layoffs signals that the...
US Homeownership Rate Falls to Lowest Level in 5 Years
By Naveen Athrappully The homeownership rate in the United States declined to 65.1 percent in the first quarter of this...